Three of the four candidates running in the Arlington County Board race responded to an Equity Arlington questionnaire about ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the company’s commitment to make at least two million doses of ...

Foxit, a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase their productivity and do more with documents, today announced it will be ...

Uganda Women’s Effort to Save Orphans (UWESO) is an indigenous Non-Governmental Organization registered with the Uganda NGO Board and is committed to improving the quality of life of orphans and other ...

Uganda Women’s Effort to Save Orphans (UWESO) is an indigenous Non-Governmental Organization registered with the Uganda NGO Board and is committed to improving the quality of life of orphans and other ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Researchers from the HIV Prevention Trials Network (HPTN ... acceptability and feasibility of an integrated multicomponent strategy to enhance daily oral HIV pre-exposure prophylaxis (PrEP ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

This dynamic gathering provided a platform for experts to share cutting-edge evidence and discuss the latest tools and strategies in HIV prevention science. The week-long event included 16 invited ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

Lenacapavir's biannual administration may reduce stigma and improve adherence to HIV prevention strategies. New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV ...

An HIV prevention injection that provides six months of protection ... Gilead is "exploring several innovative strategies to support access to LEN for PrEP (if approved), including tiered pricing, and ...